XML 48 R24.htm IDEA: XBRL DOCUMENT
v3.19.3

Revenues (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2019
Revenue from Contract with Customer [Abstract] |
Disaggregation of revenue by product and by geographic area | Revenues were as follows (in millions):
|  | Three months ended September 30,
|  | 2019 |  | 2018
|  | US |  | ROW |  | Total |  | US |  | ROW |  | Total
Enbrel® (etanercept) |  | $ | 1,323 |  |  | $ | 43 |  |  | $ | 1,366 |  |  | $ | 1,242 |  |  | $ | 50 |  |  | $ | 1,292 |
Neulasta® (pegfilgrastim) |  | 619 |  |  | 92 |  |  | 711 |  |  | 897 |  |  | 154 |  |  | 1,051 |
Prolia® (denosumab) |  | 425 |  |  | 205 |  |  | 630 |  |  | 354 |  |  | 178 |  |  | 532 |
XGEVA® (denosumab) |  | 356 |  |  | 120 |  |  | 476 |  |  | 323 |  |  | 110 |  |  | 433 |
Aranesp® (darbepoetin alfa) |  | 204 |  |  | 248 |  |  | 452 |  |  | 248 |  |  | 229 |  |  | 477 |
KYPROLIS® (carfilzomib) |  | 163 |  |  | 103 |  |  | 266 |  |  | 142 |  |  | 90 |  |  | 232 |
EPOGEN® (epoetin alfa) |  | 215 |  |  | — |  |  | 215 |  |  | 252 |  |  | — |  |  | 252 |
Sensipar®/Mimpara® (cinacalcet) |  | 38 |  |  | 71 |  |  | 109 |  |  | 330 |  |  | 79 |  |  | 409 |
Other products |  | 686 |  |  | 552 |  |  | 1,238 |  |  | 472 |  |  | 360 |  |  | 832 |
Total product sales(1) |  | $ | 4,029 |  |  | $ | 1,434 |  |  | 5,463 |  |  | $ | 4,260 |  |  | $ | 1,250 |  |  | 5,510 |
Other revenues |  |  |  |  |  | 274 |  |  |  |  |  |  | 394 |
Total revenues |  |  |  |  |  | $ | 5,737 |  |  |  |  |  |  | $ | 5,904 |
|  | Nine months ended September 30,
|  | 2019 |  | 2018
|  | US |  | ROW |  | Total |  | US |  | ROW |  | Total
ENBREL |  | $ | 3,744 |  |  | $ | 136 |  |  | $ | 3,880 |  |  | $ | 3,544 |  |  | $ | 155 |  |  | $ | 3,699 |
Neulasta® |  | 2,231 |  |  | 325 |  |  | 2,556 |  |  | 2,854 |  |  | 452 |  |  | 3,306 |
Prolia® |  | 1,273 |  |  | 647 |  |  | 1,920 |  |  | 1,070 |  |  | 566 |  |  | 1,636 |
XGEVA® |  | 1,091 |  |  | 355 |  |  | 1,446 |  |  | 994 |  |  | 336 |  |  | 1,330 |
Aranesp® |  | 578 |  |  | 724 |  |  | 1,302 |  |  | 714 |  |  | 689 |  |  | 1,403 |
KYPROLIS® |  | 483 |  |  | 295 |  |  | 778 |  |  | 430 |  |  | 287 |  |  | 717 |
EPOGEN® |  | 657 |  |  | — |  |  | 657 |  |  | 746 |  |  | — |  |  | 746 |
Sensipar®/Mimpara® |  | 216 |  |  | 228 |  |  | 444 |  |  | 1,069 |  |  | 257 |  |  | 1,326 |
Other products |  | 1,889 |  |  | 1,451 |  |  | 3,340 |  |  | 1,353 |  |  | 1,016 |  |  | 2,369 |
Total product sales(1) |  | $ | 12,162 |  |  | $ | 4,161 |  |  | 16,323 |  |  | $ | 12,774 |  |  | $ | 3,758 |  |  | 16,532 |
Other revenues |  |  |  |  |  | 842 |  |  |  |  |  |  | 985 |
Total revenues |  |  |  |  |  | $ | 17,165 |  |  |  |  |  |  | $ | 17,517 |
____________ (1) Hedging gains and losses, which are included in product sales, were not material for the three and nine months ended September 30, 2019 and 2018.

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration